Anavex Life Sciences has reported encouraging data from its Phase 2b/3 clinical trial of Anavex 2-73, an
oral therapy aimed at treating early Alzheimer’s disease. Anavex’s
investigational drug, also known as blarcamesine, has been shown to
significantly slow both cognitive and functional decline in patients.
The clinical trial enrolled 509 participants aged between 60 and 85, all diagnosed with mild
cognitive impairments or mild dementia due to Alzheimer’s disease. Participants
were randomly assigned to receive oral capsules of one of two doses of Anavex
2-73 or a placebo for 48 weeks. The primary goals were to assess the drug’s
impact on cognition, using the Alzheimer Disease Asses sment Scale-Cognition
(ADAS-Cog), and overall function, via the Alzheimer’s Disease Cooperative
Study-Activities of Daily Living Scale (ADCS-ADL).
Dr. Michael Weiner, a professor at the University of California, San Francisco, highlighted the
significance of these findings, noting that the data demonstrate an objective
slowing of markers of neurodegeneration. Specifically, those treated with Anavex 2-73 showed an 84% higher likelihood of meaningful cognitive
improvement compared to those on a placebo.
Additionally, blood analyses indicated a favorable increase in the ratio of two forms of
amyloid-beta proteins, which are associated with Alzheimer’s risk. Brain MRI
imaging further revealed a significant reduction in brain volume loss for those on the active treatment.
Dr. Marwan Noel Sabbagh, of the Barrow Neurological Institute, emphasized the drug’s benefits,
stating that Anavex 2-73’s small oral molecule structure and excellent safety
profile make it a promising treatment for early Alzheimer’s.
Anavex Life Sciences is preparing to meet with regulatory authorities across the U.S.,
Europe, and Asia-Pacific to discuss potential approval for Anavex 2-73. Anavex’s development brings hope to millions affected by Alzheimer’s disease
and represents a significant step forward in the battle against this debilitating condition.
See related link for more information.
Learn more about Anavex on https://www.sotcanalytics.com/update-compendium-2024#h.874e6qgoo0o6